Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study-Reference-Cited by-同舟云学术

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study

Published:2014-12-28 Issue:6 Volume:168 Page:824-834
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kirschey Sebastian¹,Flohr Thomas²,Wolf Hans H.³,Frickhofen Norbert⁴,Gramatzki Martin⁵,Link Hartmut⁶,Basara Nadezda⁷,Peter Norma⁸,Meyer Ralf G.¹,Schmitz Norbert⁹,Weidmann Eckhart¹⁰,Banat Andre¹¹,Schulz Andrea¹,Kolbe Karin¹,Derigs Guenter¹²,Theobald Matthias¹,Hess Georg¹

Affiliation:

1. Department of Haematology; Oncology and Pneumology; University Medical School of the Johannes Gutenberg University Mainz; Mainz Germany

2. Onkologische Gemeinschaftspraxis; Mainz Germany

3. Martin-Luther-University; Halle-Wittenberg Germany

4. HSK; Dr.-Horst-Schmidt-Kliniken; Wiesbaden Germany

5. University of Erlangen-Nürnberg; Nürnberg Germany

6. Westpfalz-Klinikum Kaiserlautern; Kaiserslautern Germany

7. Malteser Krankenhaus St. Franziskus-Hospital; Flensburg Germany

8. Carl-Thiem-Klinikum; Cottbus Germany

9. Asklepios-Klinik St. Georg; Hamburg Germany

10. Klinikum Nordwest; Frankfurt Germany

11. Department of Internal Medicine; Gesundheitszentrum Wetterau gGmbH; Bad Nauheim Germany

12. Städtisches Klinikum Frankfurt-Höchst; Frankfurt Germany

Funder

Roche

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13234/fullpdf

Reference48 articles.

1. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group;Blay;Blood,1998

2. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen;Bosly;Journal of Clinical Oncology,1992

3. Stem cell function and engraftment is not affected by ;in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma;Buckstein;Seminars in Oncology,1999

4. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors;Caballero;Bone Marrow Transplantation,1997

5. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Classification of Conditioning Regimens;Basics of Hematopoietic Stem Cell Transplant;2023

2. Carmustine in the Therapy of B-Cell Lymphomas;Clinical oncohematology;2021

3. Mantle cell lymphoma;Critical Reviews in Oncology/Hematology;2020-09

4. Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma;PLOS ONE;2020-07-08

5. The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies;Bone Marrow Transplantation;2018-11-02